EPISODE · Jan 25, 2023 · 53 MIN
Episode 14. MRD in Multiple Myeloma
from Blood Cancer Talks · host Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
1. Excellent paper on harmonization of performing and reporting MRD in multiple myeloma: https://www.nature.com/articles/s41375-020-01012-42. Does CR really matter in the era of MRD? Landmark paper from the Spanish Group: https://pubmed.ncbi.nlm.nih.gov/35560160/3. Meta-analysis showing individual-level prognostic impact of MRD on long-term outcomes in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/33284948/4. MASTER Trial-The first trial testing MRD-adapted treatment strategy in multiple myeloma : https://pubmed.ncbi.nlm.nih.gov/34898239/
Embed this episode
What this episode covers
In this episode, we delve into MRD in myeloma with Dr. Luciano Costa and discuss the data for 3 key clinical implications: MRD as a prognostic biomarker, MRD as a tool for treatment modification, and MRD as a surrogate endpoint for drug approval.
NOW PLAYING
Episode 14. MRD in Multiple Myeloma
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.